Monoclonal gammopathy of undetermined significance (MGUS) is of considerable clinical importance to all primary care physicians given its high prevalence in the general population. It has a variable but lifelong risk for progression to hematologic cancer, such as multiple myeloma, Waldenström macroglobulinemia, or light-chain amyloidosis. In addition, MGUS has been associated with several nonmalignant but symptomatic disorders that require therapy directed toward eliminating the monoclonal gammopathy. Thus, it is important not only to understand the essentials of diagnosing and monitoring patients with MGUS but also to recognize when to refer patients with MGUS to a specialist.
Use this article to:
- Review the criteria for the diagnosis of MGUS.
- Consult a hematologist/oncologist to discuss the cancers associated with MGUS and how to monitor patients to identify these complications.
- Review the criteria for referring a patient with MGUS to a specialist.
- Test your knowledge by completing the quiz that accompanies the article and then review the correct answers.
Annals of Internal Medicine is the premier internal medicine academic journal published by the American College of Physicians (ACP). It is one of the most widely cited and influential specialty medical journals in the world.